Abstract 1928P
Background
Sclerosing Epithelioid Fibrosarcoma (SEF) and Low Grade Fibromyxoid Sarcoma (LGFMS) are ultrarare sarcomas (incidence 0.15 and 0.51/106/year respectively, PMID: 33630918) with close/similar translocations whose natural history and optimal treatment are not well known. We report on the nationwide exhaustive series of 330 patients with SEF or LGFMS in NETSARC+ since 2010.
Methods
NETSARC (netsarc.org) is a network of 26 reference sarcoma centers with specialized multidisciplinary tumor boards (MDTB). Since 2010, pathological review is mandatory for sarcoma patients and patients’ characteristics are collected in the NETSARC+ nationwide database. The characteristics of patients with SEF and LGFMS and their outcome are presented and compared.
Results
35/73 (47.9%) and 125/257(48,8%) of patients with SEF and LGFMS were female. More primary visceral, bone and trunk primary sites were observed in SEF (p<0.001). 30.1% of SEF vs 4.3% of LGFMS were metastatic at diagnosis (p<0.0001). Median size of the primary tumor was 51mm (range 10-90). For LGFMS vs 80mm (20-320) for SEF (p<0.001). Median age of LGFMS was 12 years younger than that of SEF (43 [range 4-98] vs 55 [range 10-91], p<0.001). Neoadjuvant treatment was more often given to SEF (16.4% vs 8.6%, p=0.05). More patients with LGFMS were operated first in reference centers (51% vs 26%, p<0.001).The R0 rate was 41% in LGFMS vs 16% in SEF (p<0.001). Median PFS of SEF and LGFMS were 32 and 136 months (p<0.0001) respectively. The median OS was not reached. 50-months OS was 92.6% vs 81% fr SEF (p=0.05). Median survival was 77 months after first relapse, similar for SEF and LGFMS. In multivariate analysis for PFS, SEF histotype, size of the tumor, met at diagnosis were independently correlated to survival. In multivariate analysis for OS, age, size of the tumor, met at diagnosis, but not SEF, independently correlated to survival.
Conclusions
Although sharing close molecular alterations, SEF and LGFMS have a very different natural history, clinical presentation and outcome with a higher risk of metastatic relapse in SEF. Survival after relapse is longer than with other sarcomas, and similar for SEF and LGFMS.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Centre Leon Bérard for NETSARC+ Network.
Funding
NetSARC+ (INCA & DGOS) and RREPS (INCA & DGOS), RESOS (INCA & DGOS), LYRICAN+ (INCA-DGOS-INSERM 12563), Eurosarc (FP7-278742), InterSARC (INCA), LabEx DEvweCAN (ANR-10-LABX-0061), EURACAN (EC 739521), Association DAM’s, la Fondation ARC, Infosarcome, Ligue de L’Ain contre le Cancer, La Ligue contre le Cancer funded this study.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1930P - phase II trial of avelumab in combination with gemcitabine in advanced leiomyosarcoma as a second-line treatment (KCSG UN18-06)
Presenter: Young Saing Kim
Session: Poster session 15
1931P - Ultra-rare sarcomas have worse survival compared to non-ultra-rare sarcomas: A national cancer registry study
Presenter: MIng-Jing Lee
Session: Poster session 15
1932P - First in human trial of CEB-01 for retroperitoneal soft tissue sarcoma
Presenter: Jose Antonio González
Session: Poster session 15
1933P - Perioperative chemotherapy could reduce the risk of recurrence in resected leiomyosarcoma of the vena cava (LMS-VC): A retrospective bi-centric series on 41 patients
Presenter: Thibaud Bertrand
Session: Poster session 15
1934P - Pharmacokinetics of unesbulin in a phase Ib study of patients with advanced leiomyosarcoma
Presenter: Brian Van Tine
Session: Poster session 15
1935P - Exploration of tertiary lymphatic structure in soft tissue sarcoma for the prognostic and immunotherapy response
Presenter: Wang Xiang-Xu
Session: Poster session 15
1936P - Targeted therapy of desmoplastic small round cell tumor guided by multilayered molecular profiling
Presenter: Marcus Renner
Session: Poster session 15
1937P - KM-subtraction meta-analysis of randomized controlled trials of adjuvant chemotherapy for localized resectable soft-tissue sarcoma
Presenter: Qin Jian Low
Session: Poster session 15
1938P - Assessment of clinical benefit of cancer drugs recommended in National Comprehensive Cancer Network (NCCN) guidelines for advanced soft tissue sarcomas (STS) and bone sarcomas (BS)
Presenter: Maria Aguado Sorolla
Session: Poster session 15
1939P - phase I clinical results of SQ3370, a doxorubicin-based click chemistry therapeutic in advanced solid tumor patients
Presenter: Sant Chawla
Session: Poster session 15